Ron has vast experience in the pharmaceutical & medical device industry, currently serving as a Director in several privately and publicly held companies. On his last position, Ron served as CEO of Teva Israel and V.P. Israel & Africa, Teva Pharmaceutical Industries Ltd. Ron’s core expertise are marketing, sales & distribution, M&A, Business, and Strategic Development.
Ron holds a B.Sc. in Industrial Engineering & Management of Ben-Gurion University and MBA of Tel-Aviv University.
Ron is an active tech entrepreneur and investor for 25 years. He co-founded Sapiens International (NASDAQ:SPNS) and acted as chair and chief executive of Sapiens for 4 years. He was the founder and executive chair of Precise Software Solutions (acquired by Veritas for $600M). Ron was a founder, first round investor and a board member in GVT Holding SA, a large telephone operator in Brazil, (acquired by The Vivendi Group of France for over $4.7B). He was an early investor and a board member at Wintegra (acquired by PMC Sierra for $200M).
Zohar is the CEO of NGT3 VC. Former CEO & director of Beta-O2. Served as CEO of the Technion Tech. Incubator. Led the establishment and investment of more than 50 companies, such as Prolor Biotech (sold to OPKO, NYSE: OPK), Mazor (NASDAQ: MZOR), Corindus (NASDAQ: CVRS), ReWalk (NASDAQ: RWLK).
In the past 15 years Tal has served in a number of senior R&D positions in medical device startups, mainly in the field of percutaneous heart valve replacement.
Tal holds a B.Sc. in Biomedical Engineering of Ben-Gurion University.
Founder and Chairman Moshe “Mori” Arkin is one of Israel’s most successful life sciences and pharmaceutical entrepreneurs. A renowned industrialist and generic drug specialist, he founded Arkin Holdings in 2009. Today the company owns a healthcare portfolio of $1 billion through four investment arms, with holdings in some 20 Israeli companies developing pharmaceutical drugs and equipment.
Dr. Yaniv has more than 25 years of experience in the venture capital, pharmaceutical and biotech industries. As a senior manager, skilled physician, and experienced board member, she possesses a highly developed combination of leadership, decision making and business skills. Dr. Yaniv has served as partner at Accelmed since 2012, and is a founding partner and CEO of Almeda Ventures, a healthTech-focused public R&D partnership. Dr. Yaniv holds an MD degree from the Ben-Gurion University and an MBA from the Recanati Business School at Tel Aviv University.
David has 25 years of experience in Management of medical start-Up companies and Investment companies. Previously he was the CEO of Dentack Implants and led the company from R&D to commercialization. He also served as CEO of Dyn-Bioshaf (diagnostic) and Darly Pharmaceuticals. David managed Dyn Holdings, an incubator for medical ventures and was the CEO of DCL, an investment company listed in TASE with 13 startup companies under management. David holds B.Sc. in Economic & Management, Industrial Engineering Faculty, Technion, Haifa, Israel.